Start here if you're new
what it is
LifeStance runs outpatient mental health care in clinics and online across 33 states.
how it gets paid
Last year Lifestance Health made $1.4B in revenue. Psychiatry and medication management was the main engine at $560M, or 40% of sales.
why it's growing
Revenue grew 13.9% last year. Revenue grew 13.9% vs. prior year. Operating margin was 4.7%.
what just happened
LifeStance posted $382.2M in Q4 revenue and $0.03 EPS, beating breakeven.
At a glance
B balance sheet — gets the job done, barely
357.0x trailing p/e — you're paying up for this one
0.9% return on capital — nothing to write home about
$0.02 fy2025 eps est
$6M fy2024 rev est
xvary composite: 55/100 — below average
What they do
LifeStance runs outpatient mental health care in clinics and online across 33 states.
Leaving is painful. LifeStance logged 7.9 million visits and had 7,424 licensed clinicians across 33 states in 2024. In-network benefits → your insurer's preferred doctor list → lower out-of-pocket bills, which keeps patients inside the system.
How they make money
$1.4B
annual revenue · their business grew +13.9% last year
Psychiatry and medication management
$560M
Individual, family, and group therapy
$420M
Psychological and neuropsychological testing
$210M
Virtual care and care coordination
$210M
The products that matter
core therapy visits
Outpatient Therapy
9.0M patient visits
it handled over 9.0M patient visits in 2025 and supports the core of the $1.42B revenue base. volume is already real. the harder job is getting more profit out of that volume.
core
psychiatry care
Psychiatry Services
1.0M patient base
this sits inside the same clinic model and serves the same 1.0M patient base. you care because selling more care to an existing patient is cheaper than constantly finding a new one.
adjacent growth
payer channel
Commercial Insurance
$1.28B · 90% of revenue
this is where the money comes from. when 90% of revenue flows through commercial plans, reimbursement friction matters more than branding.
pays the bills
Key numbers
$1.4B
annual revenue
You are looking at a $1.4B sales base with only $0.02 of 2025 EPS. That gap is the whole story.
940,000
patients
That many unique patients in 2024 means LifeStance has repeat usage, not one-off transactions.
7.9M
visits
Visits are the billing engine here. More visits mean more revenue events.
$414M
long-term debt
Debt equals 14% of capital, so lenders still take a real claim before shareholders do.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $414M (14% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for LFST right now.
source: institutional data · return history unavailable
What just happened
beat estimates
LifeStance posted $382.2M in Q4 revenue and $0.03 EPS, beating breakeven.
Revenue grew 13.9% vs. prior year. Operating margin was 4.7%, and the latest coverage put gross margin near 32.5%.
$382.2M
revenue
$0.03
eps
32.5%
gross margin
the number that mattered
The $382.2M quarter matters because it shows LifeStance can grow 13.9% while still pushing toward profit.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the main risk is a thin-margin healthcare network carrying legal, reimbursement, and execution pressure at the same time. when operating margin is only 4.7%, you do not need a disaster for the numbers to wobble.
high
regulatory and legal overhang
the company has disclosed litigation and regulatory investigations, including privacy and securities-related matters. for a mental health platform handling sensitive patient data, that is not side noise. it is cost, distraction, and reputational pressure at the same time.
with q4 operating margin at 4.7%, legal spend does not need to get very large to matter.
med
commercial insurance concentration
$1.28B of revenue, or 90% of the total, comes from commercial insurance. if reimbursement rates tighten, claim denials rise, or payer contracting gets tougher, most of the income statement feels it at once.
this touches almost the entire $1.42B revenue base.
low
margin repair stalls
the business improved q4 operating margin to 4.7%, but return on capital is still only 0.9%. if progress pauses, you are left paying 357.0x trailing earnings for a business that still looks unfinished.
even healthy visit volume can disappoint shareholders if profitability stops climbing.
90% of revenue runs through commercial insurance, long-term debt is $414M, and operating margin is still 4.7%. Small execution misses matter quickly when the margin for error is this thin.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings update
you want to see whether the 4.7% q4 operating margin holds or builds. revenue growth alone is not enough anymore.
metric
operating margin
this is the cleanest scoreboard number on the page. if margin moves up from 4.7%, the thesis gets simpler. if it slips, the stock has less to lean on.
risk
litigation and privacy headlines
this is not side noise. healthcare companies handling patient data do not get cheap mistakes, especially when profitability is still thin.
trend
commercial insurance mix
90% of revenue comes through commercial insurance. if reimbursement pressure builds, the story changes before headline revenue does.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak, the street does not have a clean shared view.
risk profile
volatile
a 5 / 100 price stability score translates to a stock that swings harder than the underlying business numbers.
chart momentum
stock-specific
this name is more likely to react to execution, reimbursement, and legal headlines than to a smooth market trend.
earnings predictability
40 / 100
the company is still changing shape, so quarter-to-quarter earnings can look messier than revenue.
source: institutional data
Institutional activity
institutional ownership data for LFST is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive